Guardant Health secured FDA approval for its upgraded Guardant360 Liquid CDx, a blood-based comprehensive genomic test designed to expand tumor profiling for patients with advanced cancer. The new assay increases the analyzed genomic footprint by about 100-fold versus previously approved Guardant360 versions and captures both genomic and epigenomic information from a single blood draw. Guardant said the seven companion diagnostic indications approved for the prior Guardant360 CDx versions transfer to the upgraded test, including use for companion diagnostics in non-small cell lung cancer and colorectal cancer. Guardant also highlighted sensitivity improvements for circulating tumor DNA (ctDNA), with the aim of uncovering insights beyond genomics alone. The approval follows a broader shift toward more information-rich liquid biopsy workflows, where companies are differentiating on analytical depth and actionable interpretation rather than test availability alone.